Sales in Q2 were in line with our forecast and showed strong growth of sales related to warm perfusion. The gross margin for non-durable goods was also in line with our expectations, but higher-than-expected sales of durable goods resulted in an EBITDA margin slightly below our forecast. Overall, we keep a positive view on the report, focusing on the sales result for sales related to warm perfusion. We will return with an updated analysis shortly.